Mr. Xiaohui Li joined University of Maryland for research of antibody engineering in 1997. He worked in US biopharmaceutical industry for 8 years in companies of Amgen and BioReliance, and had experience of working on products of different stages such as preclinical, Phase I/II/III and commercialized products. Then he worked in Chinese industry for 9 years. He is currently VP of manufacturing in Genor Biopharma. His achievements include improving productivity to over 3 g/L within a year of 2009, establishing R&D labs, pilot plant, clinical and commercial manufacturing. The anti-VEGF antibody led by him was supported by "12.5" national grant to obtain IND approval.